Dasatinib Anhydrous

CHEMBL1421 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

488.0 g/mol

LogP

3.6

Phase

4

The anhydrous crystal form of dasatinib, a BCR-ABL tyrosine kinase inhibitor used for CML and Ph+ ALL. The anhydrous form represents a specific polymorphic crystal structure used in pharmaceutical manufacturing.

分子量

488.0000 g/mol

LogP

3.60

TPSA

135.00 Å²

リピンスキーの五則

適合

治療領域

Pancreatic Cancer Lymphoma Breast Cancer Prostate Cancer Leukemia

作用機序

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1

InChI

InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

Molecular Formula

C22H26ClN7O2S

HBD / HBA

3 / 9

回転可能結合数

7

重原子数

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

The anhydrous crystal form of dasatinib, a BCR-ABL tyrosine kinase inhibitor used for CML and Ph+ ALL. The anhydrous form represents a specific polymorphic crystal structure used in pharmaceutical manufacturing.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Dasatinib Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1421. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3062316. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Dasatinib Anhydrous PillFYIで

構造

クイックデータ

分子式: C22H26ClN7O2S

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.